Among 199 patients treated with thalidomide for multiple myeloma, four thromboses occurred in 49 cases during erythropoietin therapy (prevalence 8.1%; annual rate 7.25%), and another 14 events occurred in patients not on erythropoietin (9.3%; 7.56%). Thus, erythropoietin would seem not to increase the risk of thrombosis of myeloma patients receiving thalidomide.
Figures & Tables
Vol. 89 No. 9 (2004): September, 2004 : Letters to the Editor
Ferrata Storti Foundation, Pavia, Italy
Statistics from Altmetric.com
How to Cite
M Galli, F Elice, C Crippa, B Comotti, F Rodeghiero, T Barbui. Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma. Haematologica 2004;89(9):1141-1142; https://doi.org/10.3324/%x.